Insider Transactions in Q1 2021 at Mirati Therapeutics, Inc. (MRTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Shalini Sharp |
BUY
Grant, award, or other acquisition
|
Direct |
2,424
+50.0%
|
-
|
|
Mar 19
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,369
-2.77%
|
$416,944
$176.56 P/Share
|
|
Mar 19
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,369
+7.51%
|
$270,066
$114.33 P/Share
|
|
Mar 10
2021
|
Braslyn Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
410
-0.0%
|
$80,360
$196.38 P/Share
|
|
Mar 10
2021
|
Braslyn Ltd. > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
410
+0.01%
|
-
|
|
Mar 09
2021
|
Braslyn Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
11,971
-0.08%
|
$2,346,316
$196.2 P/Share
|
|
Mar 09
2021
|
Braslyn Ltd. > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
11,971
+0.38%
|
-
|
|
Mar 05
2021
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
400,005
-7.3%
|
$72,400,905
$181.07 P/Share
|
|
Mar 05
2021
|
Boxer Capital, LLC |
BUY
Exercise of conversion of derivative security
|
Direct |
611,440
+12.58%
|
-
|
|
Mar 02
2021
|
Julie M Cherrington |
SELL
Open market or private sale
|
Direct |
2,000
-28.97%
|
$404,000
$202.0 P/Share
|
|
Feb 02
2021
|
Bruce L A Carter |
SELL
Open market or private sale
|
Direct |
2,250
-14.56%
|
$432,000
$192.4 P/Share
|
|
Feb 02
2021
|
Bruce L A Carter |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+28.21%
|
$13,500
$6.78 P/Share
|
|
Feb 02
2021
|
Daniel Faga EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,340
-4.19%
|
$259,960
$194.38 P/Share
|
|
Feb 02
2021
|
Daniel Faga EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,340
+4.02%
|
$152,760
$114.33 P/Share
|
|
Jan 29
2021
|
Maria E Martinez |
SELL
Open market or private sale
|
Direct |
7,500
-10.55%
|
$1,515,000
$202.61 P/Share
|
|
Jan 29
2021
|
Maria E Martinez |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+40.6%
|
$292,500
$39.76 P/Share
|
|
Jan 26
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,292
+1.99%
|
$11,460
$5.4 P/Share
|
|
Jan 21
2021
|
Craig A Johnson |
SELL
Open market or private sale
|
Direct |
15,000
-22.59%
|
$3,180,000
$212.35 P/Share
|
|
Jan 21
2021
|
Craig A Johnson |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+44.81%
|
$300,000
$20.54 P/Share
|
|
Jan 19
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,245
+2.85%
|
$87,615
$27.0 P/Share
|
|
Jan 15
2021
|
Daniel Faga EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,023
+18.65%
|
-
|
|
Jan 15
2021
|
Faheem Hasnain |
BUY
Grant, award, or other acquisition
|
Direct |
2,098
+29.16%
|
-
|
|
Jan 15
2021
|
Aaron I. Davis |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+3.51%
|
-
|
|
Jan 15
2021
|
Julie M Cherrington |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Craig A Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Michael G Grey |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+20.47%
|
-
|
|
Jan 15
2021
|
Henry J Fuchs |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Maria E Martinez |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Bruce L A Carter |
BUY
Grant, award, or other acquisition
|
Direct |
1,475
+29.8%
|
-
|
|
Jan 15
2021
|
Charles M Baum Founder, President, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
19,665
+15.5%
|
-
|
|
Jan 15
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,023
+11.46%
|
-
|
|
Jan 15
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,023
+20.76%
|
-
|
|
Jan 15
2021
|
Vickie S Reed SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,157
+26.34%
|
-
|
|
Jan 07
2021
|
Daniel Faga EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,625
-5.0%
|
$564,375
$215.82 P/Share
|
|
Jan 07
2021
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,078
-4.75%
|
$446,770
$215.82 P/Share
|
|
Jan 07
2021
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
241
-3.13%
|
$52,056
$216.33 P/Share
|
|
Jan 06
2021
|
Charles M Baum Founder, President, and CEO |
SELL
Open market or private sale
|
Direct |
4,511
-2.45%
|
$960,843
$213.02 P/Share
|
|
Jan 06
2021
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,459
-1.5%
|
$310,767
$213.07 P/Share
|
|
Jan 06
2021
|
Vickie S Reed SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
538
-3.26%
|
$114,056
$212.99 P/Share
|